Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


About us

MEDtalks is an independent multidisciplinary Internet TV channel for medical professionals. Congress News, Discussion Rounds, Interviews with scientists, research results, and accredited refresher courses will be published on this website for registered healthcare professionals.


Login Register

Featured Articles

Congress news 24/08/2020

2nd Swiss ECHO

ECHO: Exchange in Clinical Hematology & Oncology   During this multi-disciplinary educational event, hot topics in Prostate Cancer, Breast Cancer as well as in Chronic Lymphocytic Leukemia, Multiple Myeloma, and beyond were addressed. To emphasize the interdisciplinary approach, the program also contains highly interesting topics relevant in the daily practice of both of you, Hematologists and Oncologists. This event aims to combine important clinical data with practical relevance and an enhanced professional network for all of you.   You can review the following presentations and discussions by clicking on this link:   Key note Lecture: «Immunotherapy: beyond check points and CARs» Prof. Heinz Läubli, University Hospital Basel   CLL: «Fixed duration vs MRD driven therapy of CLL» Prof. Davide Rossi, EOC Bellinzona   Prostate Cancer: «Personalized therapy for metastatic prostate cancer: dream or reality?» Dr. Ursula Vogl, EOC Bellinzona   Hot topic in Cancer: «Circulating Tumor Clusters» Prof. Nicola Aceto, University of Basel   MM: «Immunotherapies in management of Multiple Myeloma» Prof. Martin Kortüm, University Clinic Würzburg   Breast cancer: «Management of ER+, HER2- locally metastatic breast cancer» Prof. Giuseppe Curigliano, European Institute of Oncology and University of Milano   Many thanks also to the scientific committee which was formed with the experts mentioned below: PD Dr. Cathomas (Oncology, Kantonsspital Graubünden, Chur) Prof. Dr. Matthes (Hematology, Hôpitaux Universitaires Genève, Geneva) Prof. Dr. Renner (Oncology/Hematology, OnkoZentrum Hirslanden, Zürich) Prof. Dr. Pagani (Cancérologie, Hôpital Riviera Chablais VD-VS, Rennaz)

Congress news 20/07/2020

ACR in the Mountains

---- for registration please scroll down ----   ACR in the Mountains brings the Annual Meeting of American College of Rheumatology to Switzerland     Due to Covid-19, the ACR Annual Meeting will be held fully virtual under the name ACR Convergence 2020. It is the world’s premier virtual rheumatology experience that provides access to hundreds of sessions to educate professionals in every segment of rheumatology. Parallel to the ACR Convergence   Parallel to the ACR Convergence 2020, we offer the ACR in the Mountains – a face-to-face meeting that offers a concise wrap up of the practice-changing studies.  The "ACR in the Mountains" will take place from November 9 — 10, 2020, in the Hotel Pax Montana in Flüeli-Ranft, Obwalden. Discussion and wrap up of the congress news The Scientific Committee will select the most important news and discuss it directly with experts in multiple blocks divided according to subject areas. Original authors will be invited in a live connection to join the discussion of their studies. The participants will watch and review the most important results of the ACR Convergence 2020 and discuss their translation into the Swiss practice with the Steering Committee.   This year’s ACR in the Mountains Steering Committee consists of the following experts:   Program November 8th afternoon arrival 19.00 Joint Dinner   November 9th 8.00 – 8.05 Welcome  8.05 – 10.00 Session I: Arthrosis 10.00 – 10.30 Break 10.30 – 12.30 Session II: Covid-19: 12.30 – 13.30 Lunch 13.30 – 15.30 Session III: SPA/PSA 15.30 – 16.00 Break 16.00 – 18.00 Session IV: Pain Medicine 18.00 – 18.15 Wrap-up day 1 19.00 Joint Dinner   November 10th 8.00 – 10.00 Session V: Connectivitis 10.00 – 10.30 Break 10.30 – 12.30 Session VI: Crystal Arthritis 12.30 – 13.30 Lunch 13.30 – 15.30 Session VII:  Vaskulitis 15.30 – 16.00 Break 16.00 – 18.00 Session VIII: RA 18.00 – 18.15 Wrap-up day 2 From 18.15 Apéro & Departure   Registration Please register below. We will send you an invoice for your participation after your registration via email.   var exampleCallback = function() { console.log('Order complete!'); }; window.EBWidgets.createWidget({ // Required widgetType: 'checkout', eventId: '114243744114', iframeContainerId: 'eventbrite-widget-container-114243744114', // Optional iframeContainerHeight: 425, // Widget height in pixels. Defaults to a minimum of 425px if not provided onOrderComplete: exampleCallback // Method called when an order has successfully completed });     Under the patronaged of Licensed by  

Other 21/09/2020

Anticoagulation in GI tumor patients: When is this really useful?

PD Dr. med. Lars Asmis, Head of the Center for Perioperative Thrombosis and Hemostasis, presents "Anticoagulation in GI tumor patients: When is this really useful?“. In his lecture, he refers to the daily practical challenges and provides many useful explanations.   Presentation in German

Congress news 06/07/2020

Upper GI - Highlights WCGIC

In this presentation, Thomas Winder, Swiss Tumor Molecular Institute, Zurich covers the most important findings from the ESMO WCGIC for upper GI.   He selected the following studies and topics:   Adenocarcinoma O-10: Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010 David Ilson et al., Rhode Island, USA   O-11: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, openlabel study (DESTINY-Gastric01) Kensei Yamaguchi et al. O-12: KEYNOTE-061: response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma Harry H. Yoon et al., Rochester, MN, USA   Pancreatic Cancer LBA-1: First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Primary analysis from a phase 1/2 study Zev Wainberg et al., Los Angeles, CA, USA   PD-6: Gemcitabine + nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a population-based, multicenter AGEO study. Sonia Zaibet et al., Paris, France   Cholangiocarcinoma SO-5: Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis Milind Javle et al.   HCC O-8: Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150 Daneng Li, Duarte, CA, USA   GIST O-13: Efficacy and safety of ripretinib as ≥4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from INVICTUS César Serrano et al., Barcelona, Spain   return to overview

Congress news 06/07/2020

Lower GI - Highlights WCGIC

In this presentation, Sara De Dosso, Oncology Institute of Southern Switzerland, Bellinzona covers the most important findings from the ESMO WCGIC for lower GI / colorectal cancer.   She selected the following studies and topics:   Colon cancer adjuvant   O-16: Relative Impact of T4 and N2 on the Efficacy of 3 versus 6 Months of Adjuvant CAPOX for High-Risk Stage II and Stage III Colon Cancer: ACHIEVE and ACHIEVE-2 Trials Takeharu Yamanaka et al., Yokohama, Japan   mCRC BRAF V600E mutated LBA-5: ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAFV600E–mutant metastatic colorectal cancer Axel Grothey et al., Tennessee, USA     SO-26: Clinical efficacy of combined PD-1/BRAF/MEK inhibition in BRAFV600 colorectal cancer patients Ryan B. Corcoran et al., Boston, MA, USA     mCRC Targeting genomic drivers of the disease SO-24: AMG510 (sotorasib), A Novel Small Molecule Inhibitor of KRASG12C, For Patients With Advanced Gastrointestinal Tumors: Results From the CodeBreak100 Phase 1 Trial John H. Strickler et al., North Carolina, USA     Liquid biopsies in mCRC O-21: METABEAM Study A combined analysis of concordance studies between liquid and tumour tissue biopsies for RAS mutations in colorectal cancer patients with a single metastasis site Yoshinori Kagawa et al., Hyogo, Japan   SO-34: Experience of a Personalized and Tumor-Informed Circulating Tumor DNA Assay for Minimal Residual Disease Detection in Oligometastatic Colorectal Cancer Patients Stacey A. Cohen University of Washington et al., Division of Oncology, Seattle, WA     Rectal cancer SO-37: Short-term results of VOLTAGE-A: nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer (EPOC 1504) Satoshi Yuki et al., Sapporo, Japan   return to overview  

Congress news 06/07/2020

Highlights from WCGIC

Summaries of the most important findings from the ESMO World Congress on GI Cancer (WCGIC)   Two Swiss experts are presenting in concise wrap-up summaries the most important findings of the WCGIC. In a vivid discussion, 5 swiss and german experts evaluate the new results in terms of their clinical practice.   Lower GI & Colorectal Cancer - Sara De Dosso Upper GI - Thomas Winder Discussion Round on the Highlights from the WCGIC   Gastro-intestinal inférieur - Sara De Dosso Gastro-intestinale supérieure - Thomas Winder Débat sur les highlights du WCGIC        

Upcoming live Broadcasts

Congress news 20/07/2020

ACR in the Mountains

---- for registration please scroll down ----   ACR in the Mountains brings the Annual Meeting of American College of Rheumatology to Switzerland     Due to Covid-19, the ACR Annual Meeting will be held fully virtual under the name ACR Convergence 2020. It is the world’s premier virtual rheumatology experience that provides access to hundreds of sessions to educate professionals in every segment of rheumatology. Parallel to the ACR Convergence   Parallel to the ACR Convergence 2020, we offer the ACR in the Mountains – a face-to-face meeting that offers a concise wrap up of the practice-changing studies.  The "ACR in the Mountains" will take place from November 9 — 10, 2020, in the Hotel Pax Montana in Flüeli-Ranft, Obwalden. Discussion and wrap up of the congress news The Scientific Committee will select the most important news and discuss it directly with experts in multiple blocks divided according to subject areas. Original authors will be invited in a live connection to join the discussion of their studies. The participants will watch and review the most important results of the ACR Convergence 2020 and discuss their translation into the Swiss practice with the Steering Committee.   This year’s ACR in the Mountains Steering Committee consists of the following experts:   Program November 8th afternoon arrival 19.00 Joint Dinner   November 9th 8.00 – 8.05 Welcome  8.05 – 10.00 Session I: Arthrosis 10.00 – 10.30 Break 10.30 – 12.30 Session II: Covid-19: 12.30 – 13.30 Lunch 13.30 – 15.30 Session III: SPA/PSA 15.30 – 16.00 Break 16.00 – 18.00 Session IV: Pain Medicine 18.00 – 18.15 Wrap-up day 1 19.00 Joint Dinner   November 10th 8.00 – 10.00 Session V: Connectivitis 10.00 – 10.30 Break 10.30 – 12.30 Session VI: Crystal Arthritis 12.30 – 13.30 Lunch 13.30 – 15.30 Session VII:  Vaskulitis 15.30 – 16.00 Break 16.00 – 18.00 Session VIII: RA 18.00 – 18.15 Wrap-up day 2 From 18.15 Apéro & Departure   Registration Please register below. We will send you an invoice for your participation after your registration via email.   var exampleCallback = function() { console.log('Order complete!'); }; window.EBWidgets.createWidget({ // Required widgetType: 'checkout', eventId: '114243744114', iframeContainerId: 'eventbrite-widget-container-114243744114', // Optional iframeContainerHeight: 425, // Widget height in pixels. Defaults to a minimum of 425px if not provided onOrderComplete: exampleCallback // Method called when an order has successfully completed });     Under the patronaged of Licensed by  

Congress news 14/08/2020

From September 25, 2020 - Post ESMO by SAKK Young Oncology Academy

Post ESMO by SAKK Young Oncology Acadamy   The first and unique Swiss Post ESMO will be held virtually by the participants of the SAKK Young Oncology Academy. 9 young and ambitious doctors will present the most important data from ESMO along with their interpretation, reviewed by their YOA mentors.   The videos about the ESMO updates will be online here by September 25, 2020, at 20:00.  Participation free of charge       This program is an initiative of    For more information please visit sakk.ch or contact tanja.brauen@sakk.ch